Bronchial Washing Beforeand After Endobronchial Biopsy and Bronchial Brushing
NCT ID: NCT05569629
Last Updated: 2024-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
118 participants
INTERVENTIONAL
2022-10-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis to be tested: The investigators hypothesize that the diagnostic yield, with the incorporation of contemporary cytology processing techniques, of combined BW before and after endobronchial biopsy (EBBx) / bronchial brushing (BB) is higher than that of single BW after EBBx / BB.
Design and subjects: This is a prospective, randomized controlled study to be conducted in the medical department of a tertiary care hospital in Hong Kong involving patients who will receive bronchoscopy. Patients will be recruited if an endoscopically visible tumour is suspected.
Study instruments: Patients will be randomized into two groups. The diagnostic yield of confirming malignancy for endoscopically visible tumours, with the incorporation of contemporary cytology processing techniques, will be compared between obtaining BW before and after EBBx / BB, and obtaining single BW after EBBx / BB.
Main outcome measures: Only patients with a definite cytological or histological diagnosis of lung cancer will be included in further analyses. The diagnostic yield of diagnosing lung cancer between the pre \& post-EBBx/BB group and post-EBBx/BB group will be compared by the Chi-square test as an intergroup comparison.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Bronchoscope in Diagnosis of Lung Cancer
NCT05992740
Feasibility of Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Lung Cancer
NCT06141005
Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer
NCT00563420
Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer
NCT06301295
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
NCT00019201
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The sequence of these three endoscopic sampling techniques, especially the relative position of BW, has been controversial. BW obtains the return of normal saline after instilling over an endoscopically visible tumour, which contains exfoliated malignant cells from the tumour. It is logical that the shedding of malignant cells is increased after breaking or ablating the bronchial mucosa by EBBx and BB (EBBx / BB), but this hypothesis was not supported by several prospective studies. However, these studies were limited by inconsistent incorporation of BB, and a majority of them were self-controlled comparative studies. The only randomized, multi-centre study by Lee et al showed no significant difference in the diagnostic yield of BB before and after EBBx, but again, BB was not consistently performed in the study. Instead, the diagnostic yield by combining the BW before and after EBBx, with or without BB, was higher than a single BW alone. Although the BW obtained after EBBx / BB was more haemorrhagic in appearance, the interpretation was considered unaffected. Guidelines for bronchoscopy addressing the sequence of endoscopic sampling are conflicting. BTS guideline commented that the sequence of sample acquisition is not important, while the Indian guideline recommends BW should be performed both before and after EBBx / BB. The guideline issued by the American College of Chest Physicians did not address this issue. Nowadays, more sophisticated endoscopic sampling techniques, e.g. cryobiopsy, are available with a high diagnostic yield, but they usually carry higher procedural risk and are only available in tertiary centres with expertise. Therefore, it is necessary to optimize the sampling sequence with existing and widely available techniques.
The method of cytological processing plays a critical part in optimizing the diagnostic yield of BW. Conventional cytology (CC) preparation was employed in the above-mentioned studies, and the authors did not address the reason for negative BW cytology. Only Van der MA drift et al identified the problem of poor cellularity in a number of negative BW specimens. In the past decade, the introduction of liquid-based cytology (LBC) and cell block (CB) preparation to reduce unsatisfactory cytological results and eliminate obscuring factors such as blood, inflammation, and mucus has improved the overall diagnostic yield in addition to CC. CB also serves as another source of diagnostic material for immunohistochemical (IHC) and molecular studies. The recent developments in whole-slide scanners with increased throughput and z-stacking three-dimensionally reconstructed images allow for accurate and reproducible cellular quantification and cytomorphometric analysis. Digital pathology-based quantification can complement, validate and provide added analysis to the yield, diagnostic accuracy and cytological effects in different protocols for bronchoscopic sampling. With the incorporation of LBC and CB techniques and an optimal sequence of bronchoscopic sampling, the diagnostic accuracy, cellular yield and specimen quality can be further improved and guide personalized oncological treatment.
The investigators believe that combining EBBx and BB together is important to ablate a larger area of bronchial mucosa than either procedure alone, and potentially release more malignant cells during the BW. To date, there is no randomized controlled trial comparing the diagnostic yield of combined BW before and after EBBx / BB, and BW after EEBx / BB. The investigators hypothesize that the diagnostic yield, with the incorporation of contemporary cytology processing techniques, of combined BW before and after EBBx / BB is higher than that of single BW after EBBx / BB. The aim of this study is to identify the optimal position of BW in the sequence of bronchoscopic sampling in order to maximize the ability to confirm malignancy for endoscopically visible tumours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pre & post-EBBx/BB group
BW will be performed once before endobronchial biopsy and bronchial brushing, and once after endobronchial biopsy and bronchial brushing
Bronchial washing before endobronchial biopsy and brushing
Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
Post-EBBx/BB group
BW will be performed once after endobronchial biopsy and bronchial brushing
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bronchial washing before endobronchial biopsy and brushing
Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients will undergo endoscopic sampling procedures to the airway that contains the endoscopically visible tumours
* Patients who are aged 18 years old or above
* Patients are cognitively capable to consent for the procedure and the study
* Patients with endoscopically visible tumours in the airway during bronchoscopy, that can be approached by endoscopic sampling procedures
* Only those visible lesions with endoscopic morphology of tumorous, infiltrative, necrotic-coated types will be included
Exclusion Criteria
* Failed to obtain informed consent due to patient's refusal or cognitive impairment
* Bronchoscopy that will be performed in an emergency situation that precludes a detailed examination or prolonged procedure time, e.g. massive haemoptysis
* The prevailing contraindications for bronchoscopy or bronchoscopic samplings, e.g. uncorrected coagulopathy, and uncontrolled respiratory failure
* Lesions with an anticipated high risk of severe bleeding are found, e.g. carcinoid tumour, Dieulafoy's lesion and Kaposi sarcoma
* The targeted lesion is located in the trachea or carina
* Patients with tumours morphology of submucosal type or extrinsic compressions, or with a normal mucosal appearance in the targeted airway
* Technical reasons precluding an optimal sampling of the lesion by endoscopic sampling procedures, including sharp angulation of the airway and patient intolerance
* Excessive bleeding due to EBBx and BB causing difficult procedure of subsequent BW or premature termination of the procedure
* Coexisting tumours in the same lobar or segmental bronchi, either proximal or distal to the targeted lesion, as it is impossible to distinguish the source of exfoliated cells
* A total volume of more than 100mL of normal saline is instilled for the first BW in the combined BW group, as the total amount of normal saline after the two BW procedures may exceed 200mL and impose a risk of impaired gaseous exchange
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ka Pang Chan
Clinical Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David SC Hui, MD
Role: STUDY_DIRECTOR
Chinese University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese University of Hong Kong
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PrePostBW
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.